

Prenatal and postnatal exposure to PFAS and cardiometabolic factors and inflammation status in children from six European cohorts

Eleni Papadopoulou, PhD
Researcher

Norwegian Institute of Public Health
Global Health Cluster
Division for Health Services

Contact: elpa@fhi.no

The PROBLEMS with PFAS



HOW DOES IT GET INTO OUR BODIES?



Cooking with nonstick pans



Products containing PFAS



PFAS-contaminated food and water



PFAS in air and dust



HEALTH PROBLEMS LINKED TO PFAS

Kidney and testicular cancer

High blood pressure and pre-eclampsia

Higher cholesterol

Lower infant birth weights

Decreased vaccine response in children

PFAS

- Short for **per- and polyfluoroalkyl substances**, chemicals used in products such as non-stick cookware, food packaging, water-resistant clothing, and stain-resistant carpeting
- Also called '**forever chemicals**,' they can take up to 1,000 years to break down in nature

WHAT CAN WE DO?



INDIVIDUALS – **avoid products with PFAS** and ask policymakers to limit or ban its use

HEALTH PROFESSIONALS – **advise patients on how to avoid PFAS** and support limits on its use

BUSINESSES – **phase out use of PFAS** and avoid non-essential uses

POLICYMAKERS – **limit or ban PFAS**



<https://www.projecthelix.eu/>

Environment International 157 (2021) 106853

Contents lists available at ScienceDirect



Environment International

journal homepage: www.elsevier.com/locate/envint



Prenatal and postnatal exposure to PFAS and cardiometabolic factors and inflammation status in children from six European cohorts

Eleni Papadopoulou^{a,*}, Nikos Stratakis^{b,c}, Xavier Basagaña^{d,e,f}, Anne Lise Brantsæter^a, Maribel Casas^{d,e,f}, Serena Fossati^{d,e,f}, Regina Gražulevičienė^g, Line Småstuen Haug^a, Barbara Heude^h, Léa Maitre^{d,e,f}, Rosemary R.C. McEachanⁱ, Oliver Robinson^j, Theano Roumeliotaki^k, Eduard Sabido^l, Eva Borràs^l, Jose Urquiza^{d,e,f}, Marina Vafeiadi^k, Yinqi Zhao^b, Rémy Slama^m, John Wright^l, David V. Conti^b, Martine Vrijheid^{d,e,f}, Lida Chatzi^b

<https://www.sciencedirect.com/science/article/pii/S0160412021004785>

- de Prado-Bert P et al. The early-life exposome and epigenetic age acceleration in children. *Environ Int.* 2021.
- Julvez J et al. Early life multiple exposures and child cognitive function: A multi-centric birth cohort study in six European countries. *Environ Pollut.* 2021
- Maitre L et al. Early-life environmental exposure determinants of child behavior in Europe: A longitudinal, population-based study. *Environ Int.* 2021
- Jedynak P et al. Prenatal exposure to a wide range of environmental chemicals and child behaviour between 3 and 7 years of age - An exposome-based approach in 5 European cohorts. *Sci Total Environ.* 2021
- Granum B et al. Multiple environmental exposures in early-life and allergy-related outcomes in childhood. *Environ Int.* 2020
- Stratakis N et al. Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children. *Hepatology.* 2020
- Vrijheid M et al. Early-Life Environmental Exposures and Childhood Obesity: An Exposome-Wide Approach. *Environ Health Perspect.* 2020
- Forns J et al. Early Life Exposure to Perfluoroalkyl Substances (PFAS) and ADHD: A Meta-Analysis of Nine European Population-Based Studies. *Environ Health Perspect.* 2020
- Cadiou S et al. Using methylome data to inform exposome-health association studies: An application to the identification of environmental drivers of child body mass index. *Environ Int.* 2020
- Agier L et al Association between the pregnancy exposome and fetal growth. *Int J Epidemiol.* 2020
- Papadopoulou E et al. Diet as a Source of Exposure to Environmental Contaminants for Pregnant Women and Children from Six European Countries. *Environ Health Perspect.* 2019
- Warembourg C et al. Early-Life Environmental Exposures and Blood Pressure in Children. *J Am Coll Cardiol.* 2019
- Agier L et al. Early-life exposome and lung function in children in Europe: an analysis of data from the longitudinal, population-based HELIX cohort. *Lancet Planet Health.* 2019
- Haug LS et al. In-utero and childhood chemical exposome in six European mother-child cohorts. *Environ Int.* 2018
- Tamayo-Uria I et al. The early-life exposome: Description and patterns in six European countries. *Environ Int.* 2019
- Maitre L et al. Human Early Life Exposome (HELIX) study: a European population-based exposome cohort. *BMJ Open.* 2018

Aim- Research questions

1. What is the association between prenatal and postnatal PFAS mixture exposure and cardiometabolic health in young children?
2. What is the role of the inflammatory status?

Early life PFASs exposure



Cardiometabolic
health in childhood

Methods

Study population:

N=1,101 mother-child pairs from the Helix sub-cohort.

Pre- & Post-natal PFAS measurements


- Pregnancy: PFOA, PFNA, PFOS and PFHxS
- Childhood (mean age 8 years; range = 6 to 12 years): PFOA, PFNA, PFUnDA, PFOS and PFHxS

Child Cardiometabolic health (age and gender z-scores)

Serum Lipids: HDL cholesterol, LDL cholesterol, Triglycerides (TG)

Blood Pressure: Systolic Blood Pressure, Diastolic Blood Pressure

Waist circumference



Maternal characteristics – pregnancy.

	All (n=1101)
	<i>N (%)</i>
Cohort	
BIB	186 (17%)
EDEN	144 (13%)
KANC	188 (17%)
MOBA	209 (19%)
RHEA	166 (15%)
INMA	208 (19%)
Maternal education	
Low	166 (15%)
Medium	377 (34%)
High	558 (51%)
Parity	
Nulliparous	494 (45%)
Multiparous	607 (55%)
	<i>Mean (min-max)</i>
Maternal age (years)	31 (16-44)
Pre-pregnancy BMI (kg/m²)	25.0 (16.2-51.4)

Child characteristics.

	All (n=1101)	
	<i>N (%)</i>	
Child gender		
Boys	605 (55%)	
Girls	496 (45%)	
Child ethnicity		
White European	988 (90%)	
Other	113 (10%)	
	<i>Mean (min-max)</i>	
Age at examination (years)	8 (5-12)	
BMI (kg/m²)	16.9 (11.7, 29.6)	20% OW/OB ¹
HDL (mmol/L)	59.4 (27.1, 112.1)	3% low ²
LDL (mmol/L)	90.9 (0.7, 205)	
TG (mmol/L)	85.1 (24.8, 387.1)	
Systolic BP (in mm Hg)	99 (71-159)	2% high ³
Diastolic BP (in mm Hg)	58 (37, 110)	2% high ³
Waist Circumference (cm)	58 (21, 93)	29% high ⁴

1. Cole TJ, et al. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. *Pediatric Obesity*. 2012.

2. De Henauw S. et al. Blood lipids among young children in Europe: results from the European IDEFICS study. *Int J Obes (Lond)*. 2014

3. Barba G, et al. Blood pressure reference values for European non-overweight school children: the IDEFICS study. *Int J Obes (Lond)*. 2014

4. Nagy P et al. IDEFICS consortium. Percentile reference values for anthropometric body composition indices in European children from the IDEFICS study. *Int J Obes*. 2014.

PFASs in maternal and child samples

PFAS concentrations (in µg/L)

	Maternal samples in pregnancy				Child samples (6-12 years)				
	PFOA	PFNA	PFHxS	PFOS	PFOA	PFNA	PFUnDA	PFHxS	PFOS
Samples >LOD (%)	99.6%	97.8%	97.1%	100%	100%	99.5%	66.2%	99.7%	99.7%
10th	0.80	0.23	0.19	2.36	0.95	0.18	0.02	0.10	0.73
25th	1.34	0.42	0.30	3.99	1.17	0.29	0.03	0.18	1.22
50th	2.22	0.69	0.53	6.15	1.53	0.47	0.06	0.34	1.93
75th	3.29	1.10	0.88	9.16	1.96	0.73	0.10	0.56	3.11
90th	4.37	1.58	1.39	14.41	2.43	1.14	0.17	0.82	4.63

Spearman correlation coefficients

Maternal samples


PFNA	0.61			
PFHxS	0.65	0.29		
PFOS	0.64	0.46	0.71	

Child samples


PFOA	0.20	-0.01	0.15	0.14				
PFNA	0.16	0.21	0.20	0.39	0.44			
PFUnDA	0.21	0.14	0.19	0.28	0.25	0.51		
PFHxS	0.26	-0.11	0.50	0.47	0.40	0.39	0.33	
PFOS	0.25	0.20	0.26	0.49	0.43	0.64	0.50	0.58

Relatively low PFAS exposed study groups

Prenatal PFAS levels in different populations



Childhood PFAS levels in different populations (~8 years)



1. What is the association between prenatal and postnatal PFAS mixture exposure and cardiometabolic health in young children?

Hierarchical Bayesian kernel machine regression (BKMR):


Exposure: log-transformed PFAS in maternal & child blood

Outcome: cardiometabolic factors

Confounders: cohort, maternal age (in years), parity (nulliparous/multiparous), maternal education level (low, middle, high), maternal pre-pregnancy BMI (in kg/m²), child ethnicity (White European, Other), age at examination (in years) and sex (male/female).

❖ Sensitivity analyses: child's gender, trimester of maternal sample collection


Results – «PFAS mixture effects»




Outcomes	Direction	Dose-response	Contribution to mixture (range: 0 to 1)	
			Prenatal PFAS	Postnatal PFAS
HDL cholesterol	Positive	Yes-strong	PFHxS (0.55)	PFUnDA (0.57)
LDL cholesterol	Negative	No	PFOA (0.43)	PFOA (0.59)
Triglycerides	Negative	Yes	PFHxS (0.32)	PFUnDA (0.52)
Systolic Blood Pressure	Positive (for exposure levels >50th percentile)	Yes	PFOS (0.40)	PFNA (0.42)
Diastolic Blood Pressure	Null	Unsure	PFOS (0.34)	PFNA (0.63)
Waist circumference	Negative	Yes-strong	PFNA (0.80)	PFOA (0.97)

Results – «individual PFAS effects»

HDL cholesterol- POSITIVE



Waist circumference - NEGATIVE




2. What is the role of the child's inflammatory status?

- **N=36 proteins analyzed by three Luminex kits (child blood samples)**

Adipokines, apolipoproteins, CC chemokines, CXC chemokines, interferons, interleukins, etc.

- **Integrated network by applying the xMWAS method:**

1. pairwise data integration
2. visualization of a multi-data integrative network
3. multilevel community detection.






Fig. 2. Graph of the integrative network analysis of prenatal and postnatal PFAS, inflammatory protein concentrations in child's blood and cardiometabolic factors in childhood as derived by the xMWAS. Five communities were detected by the multilevel community detection algorithm, and are represented by different colors.

Community 1 (dark blue):

Postnatal PFUnDA, HDL-C

Community 2 (light blue):

Postnatal PFHxS and PFOS, WC, IL-1 β , IL-6, leptin and MCP1

Community 3 (green):

Prenatal PFOA, PFNA and PFOS, TG, MIP1- β

Community 4 (orange):

Postnatal PFOA, LDL-C, IL-8 and HGF

Community 5 (yellow):

Postnatal PFNA, Systolic BP, and ten inflammatory proteins

Summary



Norwegian Institute of Public Health

- **Pre- and Post-natal PFAS mixture exposure was positively associated with HDL-C and Systolic BP, and negatively associated with WC and TG.**
- **Postnatal PFASs were driving these associations with the PFAS mixture.**
- **Prenatal PFAS were associated with poorer cardiometabolic health (lower HDL-C and higher WC), but these associations were weaker.**
- **Most PFAS were negatively linked with inflammatory proteins → phenotype: Low PFAS exposure (pre & post) & obesity-induced inflammation**
- *** Prenatal PFAS → IL1-beta → adiposity***

Summary-in context of similar studies



Norwegian Institute of Public Health

- Our results confirm that gestation is a period of increased susceptibility to the detrimental effects of PFAS.
 - *Health Outcomes and Measures of the Environment (HOME) Study, Cincinnati, Ohio*
- Substantial uncertainty around this health outcome
- PFAS exposure in childhood were mostly negatively linked with the clusters of cardiometabolic factors-inflammatory proteins.
- Confirm the role of PFAS on suppression of inflammatory response
 - *suppressed antibody response to vaccination and increased occurrence of asthma, suggesting reduced immunological response, as well as lower levels of proteomic markers of inflammation*

Zoom out



Norwegian Institute of Public Health

- Need to protect vulnerable populations against serious health impacts linked to PFAS exposure. Even at background level exposures.
- The global elimination of PFOS and PFOA, the main PFAS found in biological samples worldwide, has been regulated through the Stockholm Convention (since 2009 for PFOS and since 2020 for PFOA) and this is covered by EU/EEA legislations.
- The restriction of manufacture of more PFASs has been approved and regulated (ECHA) and is to be applied in the EU/EEA.
- Room for more action → substances are currently being evaluated one at the time (i.e PFOS, PFOA) vs. entire families of chemicals (PFAS) → loopholes in current chemicals regulations → “regrettable substitutions”.
- Barriers for a common solution¹: Multiple uses- multiple sources of exposure - variability of this substance group - lack of a complete overview on substances and uses – new patents

ATHLETE (Advancing Tools for Human Early Lifecourse Exposome Research and Translation)

<https://athleteproject.eu/>



1. Set up a **prospective Europe-wide exposome cohort** covering the first two decades of the life course, building on 17 existing cohorts across Europe.
2. Measure **numerous environmental exposures** (urban, chemical, lifestyle and social risk factors) during pregnancy, childhood, and adolescence.
3. Link this “early-life exposome” with **children’s biological responses and cardiometabolic, respiratory, and mental health.**
4. Estimate the **societal impact** of the exposome by calculating economic costs and impacts for children’s health, in order to guide evidence-based policies and administrative decisions.
5. Implement **interventions for reducing exposures** related to the urban and chemical exposome.
- 6. Translate acquired knowledge for policymakers and citizens.**
7. Make exposome data, tools and results **available to researchers and policy makers** in an **online ATHLETE toolbox** for use during and after the project, including an openly accessible exposome data infrastructure.
8. Work together with nine projects as part of the [European Human Exposome Network](#) to implement the world’s largest network studying the impact of environmental exposure on human health.

Acknowledgements

Funding: Norwegian Research Council
[MILJØFORSK — Miljøforskning for en grønn
samfunnsomstilling/](#) Nr. 268465



Norwegian Institute of Public Health

- Department of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway: **Line S Haug**
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA: **Nikos Stratakis, David V Conti, Lida Chatzi**
- ISGlobal, Institute for Global Health, Barcelona, Spain: **Xavier Basagana, Maribel Casas, Serena Fossati, Léa Maitre, Jose Urquiza, Martine Vrijheid**
- Department of Environmental Sciences, Vytautas Magnus University, Kaunas, Lithuania: **Regina Gražulevičienė**
- Centre for Research in Epidemiology and Statistic (CRESS), Université de Paris, Inserm, Inra, F-75004 Paris, France: **Barbara Heude**
- Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK: **Rosemary RC McEachan, John Wright**
- School of Public Health, Imperial College London, UK: **Oliver Robinson**
- Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece: **Theano Roumeliotaki, Marina Vafeiadi**
- Proteomics Unit, Centre de Regulació Genòmica, Barcelona Institute of Science and Technology, Barcelona, Spain: **Eduardo Sabidó**
- Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Inserm, CNRS, University Grenoble Alpes, Institute of Advanced Biosciences, Joint research center (U1209), La Tronche, Grenoble, France : **Remy Slama**